A PHASE 2 STUDY OF COMBINED CHEMO-IMMUNOTHERAPY WITH CISPLATIN-PEMBROLIZUMAB AND RADIATION FOR UNRESECTABLE VULVAR SQUAMOUS CELL CARCINOMA

A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma

Abstract Background Unresectable or metastatic vulvar cancer has relatively poor outcomes despite chemotherapy-sensitized radiation therapy and combination cytotoxic therapy.Despite the virus-associated and immunogenic nature of this disease, CARDIGANS novel immunotherapy options that exploit this advantage are currently lacking.Platinum agents suc

read more